Close Menu

psychiatric conditions

Originally published May 15.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – AssureRx today announced it has secured an $8 million term and revolving credit facility, which it will use to increase adoption of its GeneSightRx test.

The story has been corrected to say that certification from New York is for AssureRx's laboratory not its GeneSightRx test.
By a GenomeWeb staff reporter

The pharmacy benefits manager will study whether its members are more willing to take -- and stick with -- antidepressant and antipsychotic drugs prescribed to them based on a genetic test that suggests they are most likely to benefit from such treatment.

The partners will use AssureRx's GeneSightRx pharmacogenetic profile test and track patients taking pychotropic medications.

Diamond Healthcare will initially provide AssureRx Health's GeneSightRx psychiatric pharmacogenetic test in 10 of its behavioral health units, but plans to expand adoption of PGx testing within its 30-state network.

AssureRx has added a fifth gene, CYP1A2, to its GeneSightRx pharmacogenomic test to guide treatment decisions for psychiatric patients.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.